| Name | Title | Contact Details |
|---|---|---|
Matt Koerner |
Partner, Chief Marketing Officer | Profile |
In 2011, KUIU was launched by founder Jason Hairston with the idea of bringing incredible technology and innovation to serious mountain hunters at fair prices. The goal was to fulfill this mission by doing business with uncompromised commitment to quality and consumer transparency. Utilizing a direct to consumer business model, KUIU has brought revolutionary equipment to the hunting industry based off of a technical layering system designed to keep you comfortable and dry in the most extreme hunting conditions. By eliminating the middleman and introducing unmatched technology at unbelievable pricing, KUIU is bringing to life its motto "Innovation Never Rests".
Medical Claims Processing and Payer Solutions are Imagenets core business. Through our Paper to EDI, Adjudication, Claims Audit, and Contact Center solutions, Imagenet partners with each of our clients to ensure their compliance and business continuity needs are met, while helping implement bottom line efficiencies. All our solutions are Client Managed solutions, meaning your organization only supplies the business rules, and we respond with the tools, infrastructure, personnel, and subject matter experts, to accomplish the goals that your organization set out to accomplish. Our success is built upon our collaborative approach to engaging and delivering solutions to our trusted client partners. From our growing list of regional and locally staffed facilities, Imagenet performs as a natural extension of our client partners by delivering our solutions from local operating centers. Regional Facilities Located In: Arizona | California | Florida | Idaho | New Jersey | Pennsylvania | Texas | Washington
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MACC Investment Group will endeavor to re-energize portfolio brands by providing consistent supportive leadership. We hold our internal support teams accountable to the task of delivering on a mission that supports improving guest transactions concurrent with growing market share. We will develop and coach behaviors that drive performance while holding our corporate team accountable in a business environment that rewards and celebrates improved diligence and fiscal responsibility.